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CACNA1C risk variant affects reward responsiveness in
healthy individuals
TM Lancaster1,2, EA Heerey3, K Mantripragada1 and DEJ Linden1,2
The variant at rs1006737 in the L-type voltage-gated calcium channel (alpha 1c subunit) CACNA1C gene is reliably associated with
both bipolar disorder and schizophrenia. We investigated whether this risk variant affects reward responsiveness because reward
processing is one of the central cognitive-motivational domains implicated in both disorders. In a sample of 164 young, healthy
individuals, we show a dose-dependent response, where the rs1006737 risk genotype was associated with blunted reward
responsiveness, whereas discriminability did not signiﬁcantly differ between genotype groups. This ﬁnding suggests that the
CACNA1C risk locus may have a role in neural pathways that facilitate value representation for rewarding stimuli. Impaired reward
processing may be a transdiagnostic phenotype of variation in CACNA1C that could contribute to anhedonia and other clinical
features common to both affective and psychotic disorders.
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INTRODUCTION
Although the heritability of psychiatric illness is high, the genetic
mechanisms that confer susceptibility remain relatively
unknown.1,2 Recent genome-wide association studies (GWAS)
have repeatedly identiﬁed a risk variant in the CACNA1C gene,
which encodes an L-type voltage-gated calcium channel (alpha 1C
subunit). The risk variant (rs1006737: A allele) is signiﬁcantly
associated with bipolar disorder3,4 and schizophrenia,5–8 support-
ing the hypothesis that CACNA1C contributes to the genetic
overlap between these psychiatric disorders.
The rs1006737 risk variant has also been associated with several
intermediate phenotypes such as neural activity during
episodic9–12 and working memory,13 emotional regulation,14–16
and verbal ﬂuency.17,18 Numerous studies also suggest the
rs1006737 variant may affect components of cognition, such as
logical/working memory19,20 and clinical symptomology.21,22
Furthermore, emerging evidence supports a role for rs1006737
in the neural processing of reward23 and learning.24 Considering
that the CACNA1C variant appears to transcend diagnostic
boundaries, we hypothesize that the risk variant may affect
intermediate phenotypes that are associated with several
psychiatric illnesses.
A growing body of research suggests that the neural circuitry
supporting reward processing may be a suitable platform of study,
as impaired reward function is repeatedly observed as a
component of neuropsychiatric disorders.25–30 One promising
candidate intermediate phenotype for several neuropsychiatric
disorders is response bias, as measured by the probabilistic
reward-learning task.31 The paradigm measures the development
of response bias on the basis of a differential reinforcement
schedule and indicates an individual’s propensity to respond to
reward. Reward responsiveness initially predicted an anhedonic
phenotype,31 but has since been shown to be diminished in
patients with bipolar disorder32 and more general depressive
phenotypes.33–35
Reward responsiveness may also be modulated by dopaminer-
gic innervation36,37 and interactions between stress and genes
that inﬂuence the stress-axis.38–40 Additional evidence supports a
role for gene variants that inﬂuence dopaminergic regulation.41,42
These associations are supported by ﬁndings that reward
responsiveness during the task is moderately heritable.43 How-
ever, no studies have looked at the potential association between
GWAS-identiﬁed risk variants and reward responsiveness. We
consider CACNA1C rs1006737 as a candidate variant to probe for
effects in reward responsiveness considering previous literature
suggests (a) CACNA1C is associated putative effects on reward/
learning;23,24 (b) CACNA1C is associated with mood disorders at
genome-wide level3,4,7 and (c) reward responsiveness is dimin-
ished as a component of these psychiatric illnesses.32–35 As the A
allele at rs1006737 is overrepresented in neuropsychiatric illness,
we anticipate that the genotype group with the A risk allele will
show blunted reward responsiveness compared with individuals
who do not carry a copy of the risk allele.
MATERIALS AND METHODS
Participants
Bangor site: 131 subjects were recruited from Bangor University and
genotyped for the CACNA1C variant (rs1006737). Participants in this panel
were recruited by advertisement, from among the University community
(for example, students, employees) on the basis of the following self-
reported criteria: western European descent; no experience of psychiatric/
neurological symptoms or diagnoses in either themselves or ﬁrst-degree
relatives; no illegal (or recreational) substance use/dependence (excluding
nicotine) and no alcohol abuse/dependence. Cardiff site: 34 Caucasian
volunteers were genotyped for the CACNA1C variant (rs1006737). No
participants reported any current mental illness44 or use of psychotropic
medication. The study was approved by the ethics committee of each
University and written, informed consent was given by all participants
1Neuroscience and Mental Health Research Institute and MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK; 2School of Psychology, Cardiff
University, Cardiff, UK and 3School of Psychology, Bangor University, Bangor, UK. Correspondence: Dr TM Lancaster, Neuroscience and Mental Health Research Institute, Hadyn
Ellis Building, Maindy Road, Cardiff University, Cardiff CF24 4HQ, UK.
E-mail: LancasterTM@cardiff.ac.uk
Received 23 May 2014; revised 1 August 2014; accepted 21 August 2014
Citation: Transl Psychiatry (2014) 4, e461; doi:10.1038/tp.2014.100
© 2014 Macmillan Publishers Limited All rights reserved 2158-3188/14
www.nature.com/tp
before gDNA extraction and participation. A total of 164 healthy
individuals were included in the study (sample demographics are
described in Table 1). CACNA1C rs1006737 genotype frequencies did not
signiﬁcantly differ between sites (χ2 = 1.488, P= 0.475; Table 1). Genotype
frequencies for rs1006737 did not deviate from Hardy–Weinberg
equilibrium (χ2 = 1.51, P= 0.217; Table 1). On the basis of the effect size
from a previous candidate gene-response bias study with a similar sample
size,38 we anticipate to see a small effect size (Cohen’s d= 0.38). A power
calculation45 suggested that we had 78% power to detect an effect of this
size for rs1006737 on response bias (α=0.05, one-sided).
rs1006737 SNP genotyping
Bangor site: genomic DNA was obtained from saliva using Oragene
OG-500 saliva kits for 136 participants. Genotyping of rs1006737 was
performed using the Illumina Golden Gate assay (Illumina, San Diego, CA,
USA) using the BeadXpress platform, which allows high-throughput
multiplex genotyping of SNPs. Assays were designed for the experiment
using Illumina’s Assay Design Tool (http://support.illumina.com/array/
array_software/assay_design_tool.ilmn). SNP sequence: 5′-ACTTGGCTCTAT
CAAAGTCTTGCTATCAATTACATAAGTTCCATTCCATCTCAGCCCGAA[A/G]TGT
TTTCAGAGCCGGAGACCTCACAGTGTCTCTCAGGACAGTACCTTTCAGGTTTGA
ATG-3′. Nucleic acid concentration was evaluated using PicoGreen assay
(Life Technologies, Carlsbad, CA, USA). Golden Gate genotyping was
performed according to manufacturer’s protocols. Genotype calling and
annotation were performed using GenomeStudio (Illumina). CACNA1C
rs1006737 was not available for ﬁve individuals from the Bangor site.
Cardiff site: genomic DNA was obtained from saliva using Oragene
OG-500 saliva kits for 37 participants. CACNA1C rs1006737 was genotyped
using custom SNP genotyping arrays from Illumina (Illumina). Individuals
were excluded for ambiguous sex, cryptic relatedness up to third-degree
relatives by identity of descent, genotyping completeness o97%, and
non-European ethnicity admixture detected as outliers in iterative
EIGENSTRAT analyses of an LD-pruned data set.46 Thirty four of the 37
individuals included in the sample had genotype data available for
rs1006737.
Experimental Procedure
To measure reward responsiveness, we used a line discrimination task with
asymmetric reinforcement, closely modelled after that described in
Pizzagalli et al.31 and Heerey et al.47 Asymmetric reinforcement, in which
correct responses to one stimulus receive more frequent rewards than
correct responses to another, leads to the development of response bias
by increasing participants’ likelihood of reporting the more frequently
reinforced stimulus.48 It is hypothesized that individuals who develop
greater levels of response bias are more responsive to rewards.31 Trials
began with a ﬁxation cross (500ms), followed by the presentation of a
cartoon face with no mouth. After 500ms, either a short (22mm) or long
(24mm) mouth appeared on the face. It was visible for 100ms before
disappearing. The face remained on screen until the participant responded
with a button press indicating the presence of either the short or long
mouth. Following the response, participants saw a screen that either
displayed feedback (‘correct +5 pence’) or remained blank (no-feedback
trials) for 1750ms. Participants completed three blocks of 100 trials. Both
versions of the mouth appeared equally often in pseudo-random order
such that there were no more than four successive trials of the same
mouth. Participants received reward feedback on 40 correct responses per
block. To induce a reward-related response bias in the task, we distributed
the rewards asymmetrically across the mouths. The more frequently
reinforced mouth received 30 rewards per block and the remaining 10
rewards occurred after responses to the other mouth. We used a pseudo-
random reward schedule such that no more than three correct trials in a
row received reinforcements. Participants never received feedback on
incorrect trials. When positive feedback was scheduled for a trial and the
participant answered incorrectly, the reinforcement was postponed until a
later unreinforced, correct trial (of the same mouth length) occurred. The
length (short or long) of the more frequently reinforced mouth was
counterbalanced across participants. All trials where reaction times faster
than 200ms and slower than 3000ms were removed from the analysis as
previously described.47 We measured the frequency of each participant’s
reward feedback schedule on the basis of the number of positive rewards
(‘correct +5 pence’) they received. The maximum bonus was £6 and
individuals who earned o£5 were excluded from the analysis (n = 1). The
reward feedback schedule received did not signiﬁcantly differ between
gender (F1,163 = 1.580, P= 0.210); rs1006737 genotype group (F2,163 = 0.180,
P= 0.836); across sample site (F1,163 = 0.525, P= 0.47) and did not correlate
with age (r=0.084, P= 0.285).
A post-task debrieﬁng interview conﬁrmed that no participants were
aware of the reinforcement asymmetry. We used a standard signal
detection analysis to calculate d’, a measure of discrimination accuracy
[d= z(H)− z(F)] and ‘criterion,’ the degree to which participants showed a
bias towards the more frequently reinforced mouth (c=− 1/2[z(H) = z
(F)];47,48). Please note that we reversed the values for criterion in the
analysis (positive values represent a higher propensity for developing
response bias), for ease of interpretation.
RESULTS
Effects of demographic factors
There were no site speciﬁc differences in participants’ ability to
discriminate between the mouths (F1,163 = 1.999, P= 0.159) or in
the degree to which they developed response biases
(F1,164 = 1.095, P= 0.297). Therefore, data from the two sites were
combined. Moreover, data from men and women were analysed
together, as there were no signiﬁcant differences between gender
groups in either discriminability (d’) or criterion across the whole
group (both P-values 40.354) or within CACNA1C rs1006737
genotype groups (all P-values 40.111). There was a signiﬁcant
positive association between age and discriminability at block 1
(r= 0.155, P= 0.048). Therefore age was entered as a covariate into
a mixed-model analysis of covariance to assess the potential
Table 1. Descriptive statistics for CACNA1C rs1006737
CACNA1C rs1006737 AA AG GG P
Bangor site
Genotype frequencya N= 16 N= 50 N= 64 0.475
Ageb 22.06 (±3.907) 21.72 (±4.257) 21.61 (±3.736) 0.914
Gender (M/F)c N= 8/N= 8 N= 27/N= 23 N= 22/N= 42 0.097
Cardiff site
Genotype frequencya N= 7 N= 12 N= 15 0.475
Ageb 24.14 (±2.911) 24.50 (±4.056) 25.13 (±7.100) 0.919
Gender (M/F)c N= 2/N= 5 N= 6/N= 6 N= 7/N= 8 0.639
Combined sample
Genotype frequencyd N= 23 N= 62 N= 79 0.217
Ageb 22.70 (±3.698) 22.21 (±4.315) 22.23 (±4.717) 0.899
Gender (M/F)c N= 10/N= 13 N= 33/N= 30 N= 29/N= 50 0.174
aCACNA1C rs1006737 genotype frequencies between sample site tested with χ2. bGroup differences tested with one-way analysis of variance. cGender group
differences tested with χ2. dGroup differences tested for Hardy–Weinberg equilibrium. Table shows means (except where noted; s.d. appear in parentheses).
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effects of CACNA1C rs1006737 on discriminability (d’). There were
no associations between age and criterion within genotype
groups (all P-values 40.306). One additional individual’s discrimi-
nation ability was above the expected frequency (GG rs1006737
genotype); however, removing this individual did not signiﬁcantly
affect any demographic or genetic analysis. There were no
signiﬁcant outliers for the criterion measure.49 We therefore used
mixed-model analyses of variance to compare criterion across task
blocks (1–3) and genotype groups (AA= 23; AG= 62; GG= 79). We
also ran the same mixed-model analyses of variance for criterion
using a dominant genetic model (AA/AG= 85; GG= 79) as
previously described.9,23,24
CACNA1C genotype effects
Participants performed the line discrimination task equally well,
regardless of genotype group (additive genetic model:
F2,160 = 0.006, P= 0.994; dominant genetic model; F1,162 = 0.000,
P= 0.995; see Figure 1a). However, we observed CACNA1C
genotype dependent differences in reward responsiveness, such
that the risk allele was associated with diminished reward
responsiveness (additive genetic model: F2,162 = 3.374, P= 0.037,
np
2 = 0.040; dominant model: F1,163 = 5.656, P= 0.019, np
2 = 0.034;
see Figure 1b). Furthermore, in the additive genetic model, there
was a signiﬁcant task block × genotype interaction (F2,161 = 2.417,
P= 0.05, np
2 = 0.029), suggesting that genotype differences in
reward responsiveness were larger toward the end of the task
(see Figure 2). One-way analysis of variance conﬁrmed that the
largest between group difference occurred in task block 3
(F2,163 = 3.810, P= 0.024, np
2 = 0.045). Post hoc independent-
sample t-tests also revealed a dose-dependent response, in which
the largest differences in mean response bias occurred between
the AA and GG groups (pairwise comparison; pcorrected = 0.011;
Cohen’s d= 0.66). Independent samples t-test using the dominant
genetic model suggested that A risk allele carriers (AA/AG) also
had pronounced deﬁcits in reward responsiveness compared with
the nonrisk (GG) genotype group (P= 0.019; Cohen’s d= 0.37). On
the basis of our smallest effect size (Cohen’s d= 0.37), we estimate
we had 76% power to detect a signiﬁcant main effect of
rs1006737 on mean criterion (one-sided; α= 0.05).
CACNA1C genotype X task block effects
To explore the block × rs1006737 genotype interaction, we
explored variations in response bias for each genotype group at
each level. We calculated the change in criterion over the task
(Δresponse bias = block 3− block 1). A one-way analysis of
variance suggested that rs1006737 genotype related to an
individual’s propensity to develop response bias (additive mode;
F2,163 = 2.950, P= 0.05, which was driven by a difference between
the AA and AG genotype pcorrected = 0.05). We additionally
performed post hoc one-sample t-tests to test whether the
rs1006737 genotype groups (AA/AG/GG) response bias signiﬁ-
cantly differed from 0 at each block (1–3). The AA homozygous
risk group did not begin with or develop any response bias at any
block (P40.2 in all cases). The AG heterozygous risk group
showed a trend towards developing response bias (block 1: NS;
block 2: t= 1.807, P= 0.076; block 3: t= 2.643, P= 0.010), but these
results were not signiﬁcant after correction for multiple compar-
isons. However, the GG homozygous group showed signiﬁcant
response bias during all three blocks (block 1: t= 4.446, Po0.001;
block 2: t= 3.996, Po0.001 and block 3: t= 4.675, Po0.001). This
analysis indicates that the GG genotype showed response bias
early in the task, the AG genotype group started to show a
Figure 1. (a) Mean discriminability of long/short mouth types (d’) between the CACNA1C rs1006737 genotype groups. (b) Differences in mean
criterion (response bias) between the CACNA1C rs1006737 genotype groups. Horizontal lines represent median and represent 25th and 75th
percentile. Note: positive values for criterion reﬂect an increase in response bias.
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Δresponse bias in later trials, but in comparison, the AA risk group
showed no evidence of developing response bias at any point
throughout the paradigm (see Figure 2).
DISCUSSION
Previous research suggests that the CACNA1C rs1006737
risk variant is associated with heritable neuropsychiatric
disorders.3,4,8,50 Reward responsiveness is potentially heritable43
and has been shown to be disrupted in patients with bipolar and
unipolar depression.32–35 Response bias is also blunted in remitted
patients, suggesting that reward responsiveness may serve as trait
marker.33 We demonstrate for the ﬁrst time that the CACNA1C risk
variant (rs1006737: A allele) modulates an individual’s propensity
to respond to reward, without disrupting general task discrimina-
tion ability. It is an attractive feature of the reward-responsiveness
paradigm that it allows for the investigation of cognitive biases
in situations of normal discriminability, which makes it a
particularly sensitive trait marker for healthy at-risk populations.
This ﬁnding adds to a growing body of literature suggesting
that the CACNA1C variant may affect the neural mechanisms
underlying reward processing and learning.23,24,51 Blunted reward
responsiveness was seen across the whole task for AA genotype,
the rs1006736 AG genotype group showed response bias towards
the end of the task, whereas the GG nonrisk group showed reward
responsiveness throughout the task. We suggest that
rs1006737 ‘A’ risk allele dose may contribute to psychopathology
by affecting the rate of reinforcement–based learning, although
this would need to be formally tested in extended versions of the
paradigm. This ﬁnding is comparable to previous reports where
impairment in learning was most pronounced in rs1006737 A
carriers at the beginning of the task.24 These results offer novel
insight into how CACNA1C may confer susceptibility to the
neuropsychiatric illness characterized by reduced reward respon-
siveness and impairments in reward-based learning. The associa-
tion between CACNA1C rs1006737 A allele and blunted response
bias may point to a genetic basis for anhedonia, which is a
symptom common to affective and psychotic disorders.27,32,52–54
Although evidence suggests that anhedonia is a residual trait
underlying euthymic bipolar disorder,54 it is less straightforward to
align our ﬁndings with bipolar phenotypes associated with the
hyperthymic state, as it is speculated that manic states could be
associated with a potentiated rather than blunted response bias.32
Although the genetic architecture of reward-related deﬁcits and
related clinical symptoms (such as anhedonia) remains unknown,
reward responsiveness may be a promising neurobiological
process that links novel risk loci (such as SNPs identiﬁed via
genome-wide association studies) with core clinical symptoms. It
could also emerge as a promising surrogate marker for treatment
effects. A limitation of the present study was that we did not
screen for nicotine use, which may have an interactive effect on
reward responsiveness.55 We suggest that the effect of the
rs1006737 (and any other common variant) on reward respon-
siveness are likely to be small51 and thus, our sample may have
been underpowered. We therefore recommend that our results
should be treated with caution until replicated in larger,
Figure 2. Data represent the criterion (response bias) for each of the three CACNA1C rs1006737 genotype groups (as Figure 1b), but split across
the three experimental trial blocks. Horizontal lines represent median and represent 25th and 75th percentile. Note: positive values for
criterion reﬂect an increase in response bias.
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independent samples.56–58 Additional studies could further help
to verify how much variance in response bias associated with
rs1006737 genotype. Furthermore, we cannot be sure whether
rs1006737 is responsible for these effects or rather SNPs that are in
linkage disequilibrium with the variant. Nevertheless, recent GWAS
implicate CACNA1C as a suitable candidate for probing inter-
mediate traits associated with multiple neuropsychiatric illness.59
It is possible that additive variations within CACNA1C12 or
interactions with other genes60 could further modulate reward
responsiveness and explain larger proportions of variance.
In conclusion, our results suggest that the genome-wide
identiﬁed psychiatric risk locus on CACNA1C (rs1006737) may
affect an individual’s ability to respond to reward. An attractive
feature of the rs1006737 ‘A’ risk allele is its association with
increased CACNA1C mRNA expression in cortical tissue,16 which
offers putative mechanistic insight into how the variant may affect
neural circuitry. A growing body of knowledge implicates the
CACNA1C gene product in animal models of reward
processing,61–63 therefore translational animal models homolo-
gous to reward responsiveness64 may also give further insight into
the molecular mechanisms underlying the association between
CACNA1C and reward responsiveness. Future studies could also
explore the neural dynamics that support reward responsiveness
to understand how CACNA1C may exert these effects.
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